In April 2017, the FDA approved the first-ever drug treatment for the rare and aggressive skin cancer Merkel cell carcinoma (MCC). The immunotherapy drug avelumab (Bavencio, EMD Serono/Pfizer) was approved based on the results of a multicenter, open-label, phase 2 trial as well as data from a real-world retrospective analysis of patients with metastatic MCC treated with chemotherapy.
Solutions
![right arrow](/Ontada/images/icons/white-down-arrow.png?v=u3hjhmpNIp8etEtmS7upEeqmDPfsRubUgmP7L488NAo)
Life Sciences
![right arrow](/Ontada/images/icons/blue-right-arrow.png?v=4KFZ6vCSu6sqTp58mSQjR0Tul-I-DKOrhnC2bAf3LXY)
News & Events
![right arrow](/Ontada/images/icons/blue-right-arrow.png?v=4KFZ6vCSu6sqTp58mSQjR0Tul-I-DKOrhnC2bAf3LXY)
More